Allergic rhinitis is the most prevalent chronic allergic condition globally, affecting an estimated 400 million people — approximately 10–20% of the SA population. In the vast majority of cases it is well-managed with inexpensive first-line medications available at pharmacies without prescription. However, for a significant minority with moderate-to-severe persistent disease — or for those pursuing allergen immunotherapy as a disease-modifying intervention — the annual cost profile rises substantially and navigating medical aid coverage becomes more complex. This factsheet addresses the full spectrum from low-cost first-line management to allergen immunotherapy funding.
What Is Allergic Rhinitis?
Allergic rhinitis is IgE-mediated inflammation of the nasal mucosa following exposure to an aeroallergen — the nasal component of the atopic disease spectrum (which also includes asthma and atopic dermatitis). Classification:
By pattern: - Intermittent (seasonal): Symptoms on fewer than 4 days/week or fewer than 4 consecutive weeks. Typically pollen-driven — grass, tree, and weed pollen seasons in SA. - Persistent (perennial): Symptoms on 4 or more days/week for 4 or more consecutive weeks. Typically driven by house dust mite (HDM) — the most common perennial allergen in SA — or animal dander.
By severity: - Mild: Normal sleep; normal daily activities and work/school; symptoms present but not troublesome - Moderate-severe: One or more of: sleep disturbance, impaired activities, impaired work/school performance, troublesome symptoms
Common symptoms: nasal congestion, rhinorrhoea (runny nose), sneezing, nasal itch, post-nasal drip. Eye symptoms (allergic conjunctivitis) frequently co-exist. Anosmia (loss of smell) in severe disease or with co-existing nasal polyps.
The asthma connection: Up to 80% of asthma patients have allergic rhinitis. The two conditions share airway pathophysiology and are now conceptualised as one airway disease. Adequate treatment of allergic rhinitis improves asthma control, and vice versa. AURA tracks both conditions separately — if you have both, ensure both are in your profile.
No CDL, No PMB: Coverage Basics
Allergic rhinitis is not a CDL condition. There is no PMB minimum treatment benefit for chronic rhinitis management. All medications are funded from the medical savings account (MSA) or above-threshold benefit (ATB). This is usually adequate given that first-line medications are inexpensive.
The exception is allergen-specific immunotherapy (SCIT or SLIT) — the most expensive treatment layer — which many schemes fund poorly or not at all.
Treatment Ladder
Step 1 — Avoidance measures: Identify and reduce exposure to the causative allergen where possible. For HDM: allergen-proof mattress and pillow encasements (R500–R1,500 once-off), regular hot washing of bedding, reducing bedroom humidity. These are self-funded but cost-effective. For pollen: nasal saline rinses, staying indoors during peak pollen times.
Step 2 — Oral antihistamines: Second-generation, non-sedating antihistamines: cetirizine, loratadine, fexofenadine. Highly effective for sneezing, itch, and rhinorrhoea; less effective for nasal congestion. Cost: R50–R150/month. Most are available OTC — plans typically do not fund OTC medications, so these are self-funded from MSA. Generic versions are inexpensive and equivalent to brands.
Step 3 — Intranasal corticosteroids (first-line for nasal congestion): Fluticasone propionate (Flixonase), mometasone furoate (Nasonex), budesonide (Rhinocort). The most effective monotherapy for allergic rhinitis — superior to antihistamines alone because they address congestion, which antihistamines do not. Once daily. Monthly cost: R150–R250. Prescription-only; fundable through MSA on prescription.
Step 4 — Add-on and alternative therapies: - Montelukast (Singulair): Leukotriene receptor antagonist; modestly effective for rhinitis; most useful when co-existing asthma. Monthly cost: R300–R450. FDA (and SAHPRA) black box warning for neuropsychiatric effects (mood changes, suicidality) — prescribers must counsel patients. Discuss this with your doctor before starting. - Intranasal antihistamine (azelastine): Faster onset than oral antihistamines; useful for breakthrough symptoms. Monthly cost: R250–R300. - Combination intranasal steroid + antihistamine (Dymista): Fluticasone + azelastine in one spray; most effective single agent for moderate-severe allergic rhinitis. Monthly cost: R400–R550.
Step 5 — Allergen immunotherapy: The disease-modifying option: Neither antihistamines nor intranasal steroids modify the underlying allergic disease — they suppress symptoms while used. Allergen-specific immunotherapy (AIT) is the only treatment that produces long-term immune tolerance to the causative allergen, reducing both symptom severity and medication requirements — in some cases producing remission that outlasts the treatment course.
Two delivery routes: - Subcutaneous immunotherapy (SCIT): Injections administered in an allergy clinic, escalating to maintenance dose, then monthly injections for 3–5 years. Requires clinic attendance and a 30-minute wait after each injection. Monthly cost: approximately R1,200–R2,000 (build-up phase) to R800–R1,500 (maintenance). - Sublingual immunotherapy (SLIT): Daily drops or tablets administered at home. More convenient; no anaphylaxis monitoring required. Monthly cost: approximately R600–R1,000.
Coverage for immunotherapy varies widely across schemes. Most plans require exceptional-needs authorisation or do not have an explicit immunotherapy benefit. Coverage confirmation is essential before starting a 3–5 year treatment course.
Annual Cost Estimates
| Scenario | Estimated Annual Cost |
|---|---|
| Mild/intermittent — OTC antihistamine + saline rinse | R1,500 – R5,000 |
| Moderate — intranasal steroid + antihistamine prescription | R5,000 – R12,000 |
| Moderate-severe — combination spray + allergist consult | R10,000 – R20,000 |
| Allergen immunotherapy (SCIT) year 1–2 (build-up) | R20,000 – R30,000 |
| Allergen immunotherapy (SCIT) maintenance years 3–5 | R12,000 – R20,000 |
Gap Cover Relevance: Low
Allergic rhinitis rarely generates hospital admissions. Gap cover exposure is limited to allergist/immunologist consultation shortfalls (modest). Not a primary gap cover recommendation.
Plan Selection: What Matters
- Intranasal corticosteroid and combination spray formulary coverage
- Allergist / clinical immunologist specialist benefit for diagnosis and immunotherapy supervision
- SCIT or SLIT benefit — most schemes have no explicit benefit; exceptional-needs coverage varies substantially
- If co-existing asthma, the asthma CDL benefit interacts with rhinitis management; a plan with good asthma CDL coverage is beneficial for the dual-condition profile
Talk to Eldon
See which plans pay for allergic rhinitis →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).